A federal judge has dismissed legal challenges to the Medicare negotiation program brought by Bristol Myers Squibb and Johnson & Johnson, ruling that their claims of unconstitutionality are unfounded.

Within the past year, the company has eliminated more than 270 positions at its facilities in Lawrenceville, Princeton, ...

Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow. Its high debt load could turn off some risk ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Ionis ...

Bristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted ...

, opens new tab immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology ...

Bristol Myers Squibb’s products Eliquis and Farxiga were both named among the first 10 drugs eligible for Medicare negotiation, as were Xarelto, Imbruvica and Stelara from Johnson & Johnson. The ...